Patents Issued in December 20, 2018
-
Publication number: 20180362599Abstract: The present disclosure describes analog conotoxin peptides of the ?-conotoxin peptide RgIA. These analog conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain and inflammation including inflammatory pain, cancer related pain, and neuropathic pain. The RgIA analogs described in the present invention include a variety of sequence modifications and chemical modifications that are introduced to improve the drug-like characteristics of RgIA analogs and thereby increase their therapeutic value.Type: ApplicationFiled: November 6, 2015Publication date: December 20, 2018Applicant: Kineta Chronic Pain, LLCInventors: Jeffrey Jerard Posakony, Ernesto J. Munoz
-
Publication number: 20180362600Abstract: A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject.Type: ApplicationFiled: June 25, 2018Publication date: December 20, 2018Inventor: Richard John Pleass
-
Publication number: 20180362601Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.Type: ApplicationFiled: August 21, 2018Publication date: December 20, 2018Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar, Thomas Wechsler, Lei Zhang
-
Publication number: 20180362602Abstract: The present invention relates to compositions, methods and kits for promoting glucose clearance in an individual. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of insulin resistance or type 2 diabetes. The invention provides a method of promoting blood glucose clearance in an individual, the method comprising administering SMOC1 to the individual. Preferably, the individual has an impaired ability to clear glucose from the blood. Typically, the individual displays a level of insulin resistance.Type: ApplicationFiled: October 28, 2016Publication date: December 20, 2018Applicant: MONASH UNIVERSITYInventors: Matthew WATT, Ruth MEEX
-
Publication number: 20180362603Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.Type: ApplicationFiled: June 18, 2018Publication date: December 20, 2018Inventors: Amy Gilbert, Vladimir Slepushkin, Peter Emtage, Anselm Levskaya, Spencer Scott
-
Publication number: 20180362604Abstract: The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin fusion protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.Type: ApplicationFiled: May 11, 2018Publication date: December 20, 2018Inventors: Haojing Rong, Andrea Iskenderian, Angela W. Norton, Chuan Shen, Clark Pan
-
Publication number: 20180362605Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.Type: ApplicationFiled: April 10, 2018Publication date: December 20, 2018Inventors: Lei Ling, Darrin Anthony Lindhourt
-
Publication number: 20180362606Abstract: The present invention relates to a culture solution of MSCs derived from a fetus in amniotic fluid, and more specifically, to a composition for promoting hair growth or preventing hair loss, which includes a culture solution of MSCs overexpressing a reprogramming factor Nanog and derived from a fetus in amniotic fluid as an active ingredient. In addition, the present invention relates to a method for preparing the composition, which includes culturing Nanog-introduced MSCs derived from a fetus in amniotic fluid in a conditioned medium and collecting the culture solution. The conditioned medium composition according to the present invention exhibits a hair growth promoting effect, and thus is able to be used as cosmetic and pharmaceutical compositions for promoting hair growth.Type: ApplicationFiled: September 9, 2016Publication date: December 20, 2018Inventors: Seung Kwon YOU, Eun Kyoung JUN, Jung Hyun PARK, Won-Jin YUN, Da-Ryeon SON
-
Publication number: 20180362607Abstract: The present disclosure is directed to a method of treating morphine tolerance and/or symptoms associated therewith by administration to a subject in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-?.Type: ApplicationFiled: June 13, 2016Publication date: December 20, 2018Inventors: Anne Z. Murphy, Lori Eidson
-
Publication number: 20180362608Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.Type: ApplicationFiled: November 2, 2017Publication date: December 20, 2018Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
-
Publication number: 20180362609Abstract: The present invention provides a composition comprising an interferon-beta (IFN-beta) protein of which at least 80% is deamidated, a deamidated IFN-beta 1a protein, methods of producing deamidated proteins, and therapeutic uses of such compositions and deamidated IFN-beta 1a proteins.Type: ApplicationFiled: August 30, 2018Publication date: December 20, 2018Inventors: WOLF PALINSKY, MARA ROSSI, ANNA R. PEZZOTTI
-
Publication number: 20180362610Abstract: Disclosed in the present invention is a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (referred to as hFSH-Fc for short) and a preparation method thereof, wherein the hFSH-Fc protein is a dimerized fusion protein and the amino acid sequence thereof successively comprises an hFSH? subunit, CTP, an hFSH? subunit, a flexible peptide linker and human IgG2 Fc variant from N-terminal to C-terminal. Also disclosed in the present invention is the use of the recombinant hFSH-Fc fusion protein composition in preparing drugs in the animal breeding field.Type: ApplicationFiled: August 22, 2014Publication date: December 20, 2018Applicant: UnicoHealth Pharma Co., Ltd.Inventors: Yongmin Hou, Yao Lei, Henglu Deng
-
Publication number: 20180362611Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: April 11, 2018Publication date: December 20, 2018Inventors: Bjarne Due LARSEN, Jens Damsgaard MIKKELSEN, Søren NEVE
-
Publication number: 20180362612Abstract: The present invention relates to a novel epitope that converts T cell to type 1 helper T (TH1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (SEQ ID No.2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to TH1 cell and a method for converting T cell to TH1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody.Type: ApplicationFiled: January 9, 2018Publication date: December 20, 2018Inventors: Byoung S. Kwon, Seoung-Joo Lee
-
Publication number: 20180362613Abstract: Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.Type: ApplicationFiled: January 10, 2018Publication date: December 20, 2018Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: NEIL BIFULCO, JR., NATASJA BROOIJMANS, BRIAN L. HODOUS, JOSEPH L. KIM, CHANDRASEKHAR V. MIDUTURU
-
Publication number: 20180362614Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.Type: ApplicationFiled: August 29, 2018Publication date: December 20, 2018Inventors: Kuo-Jang Kao, Yun-Hsin Wang
-
Publication number: 20180362615Abstract: A method for purifying fibrinogen includes steps of: (a) precipitating fibrinogen of a fibrinogen-containing solution by adding glycine to the solution for a concentration of glycine to be 1.5 to 2.5M, and then removing a supernatant and recovering a precipitate (1st glycine precipitation); (b) dissolving the precipitate of 1st glycine precipitation of step (a) in a dissolution buffer to obtain a solution, precipitating the solution by adding glycine thereto for a concentration of glycine to be 0.2 to 1.2M, and recovering a supernatant (2nd glycine precipitation); (c) precipitating the supernatant of step (b) by adding glycine thereto for a concentration of glycine to be 1.5 to 2.5M, and recovering a precipitate (3rd glycine precipitation); and (d) dissolving the precipitate of step (c) in a dissolution buffer to obtain a solution, and subjecting the solution to nanofiltration using a nanofilter.Type: ApplicationFiled: January 12, 2017Publication date: December 20, 2018Applicant: GREEN CROSS HOLDINGS CORPORATIONInventors: Jun Sic KIM, Hyo Jin KIM, Ji Yoon PARK, Ju Ho LEE, Jae Woon SON, Yong Won SHIN
-
Publication number: 20180362616Abstract: Variants of amyloid ?-protein precursor inhibitor domain (APPI), effective in inhibiting mesotrypsin and/or kallikrein-6, and composition comprising same, are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of cancer are provided.Type: ApplicationFiled: December 8, 2016Publication date: December 20, 2018Inventors: Niv PAPO, Itay COHEN, Amiram SANANES
-
Publication number: 20180362617Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.Type: ApplicationFiled: May 11, 2018Publication date: December 20, 2018Applicant: Ablynx N.V.Inventors: ANN BRIGE, Christine Labeur, Marc Jozef Lauwereys
-
Publication number: 20180362618Abstract: The present invention provides a polyclonal antibody composition prepared from eggs of hens immunized with virulent antigens of Clostridium difficile for use in the treatment and prevention of C. difficile infections in subjects with Inflammatory Bowel Disease including Ulcerative colitis and Crohn's disease. Respective groups of hens are immunized with Toxin A or Toxin B of Clostridium difficile or a Clostridium difficile spore preparation. The polyclonal antibodies are recovered from eggs pooled from the immunized hens and the resulting antibody-egg powder is administered orally in a therapeutically effective amount to individuals infected with or suspected of being infected with C. difficile.Type: ApplicationFiled: December 18, 2017Publication date: December 20, 2018Inventor: Pradip K. Maiti
-
Publication number: 20180362619Abstract: Variant antibodies having cysteine substitutions at selected positions in the Fc region can be conjugated via the thiol group of the substituted-in cysteine.Type: ApplicationFiled: December 20, 2016Publication date: December 20, 2018Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Paul O. SHEPPARD, Henrik ANDERSEN, Xiang SHAO, Chetana RAO-NAIK, Arvind RAJPAL
-
Publication number: 20180362620Abstract: The present invention relates to anti-Ebola virus envelope glycoprotein antibodies. The invention further relates to diagnostic methods which utilize the anti-Ebola virus glycoprotein antibodies and to pharmaceutical compositions which employ these antibodies therapeutically and prophylactically.Type: ApplicationFiled: November 22, 2017Publication date: December 20, 2018Applicant: Genentech, Inc.Inventors: Mark Dennis, Mary Mathieu
-
Publication number: 20180362621Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.Type: ApplicationFiled: June 25, 2018Publication date: December 20, 2018Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
-
Publication number: 20180362622Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.Type: ApplicationFiled: June 22, 2018Publication date: December 20, 2018Applicant: Corixa CorporationInventors: Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
-
Publication number: 20180362623Abstract: The invention provides methods and compositions relating to molecular targets identified as being capable of increasing or decreasing thermogenic potential in cells, including preadipocytes. Included in the invention are methods and compositions relating to inhibiting or suppressing the activity of an uncoupling protein 1 (UCP1) negative regulator, such as cardiac actin 1 (ACTC1), somatostatin receptor 1 (SSTR1), FAT atypical cadherin 1 (FAT1), and protein tyrosine phosphatase receptor type B (PT-PRB). Also included in the invention are methods and compositions relating to activating a UCP1 positive regulator, such as phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 (PREX1), cortactin binding protein 2 (CTTNBP2), doublesex and mab-3-related transcription factor-like family A1 (DMRTA1), and endothelin receptor type B (ENDRB). The invention also provides methods and compositions relating to enrichment of cells having thermogenic potential based on cell surface markers, e.g.Type: ApplicationFiled: June 3, 2016Publication date: December 20, 2018Inventors: Yu-Hua Tseng, Matthew Lynes, Ruidan Xue
-
Publication number: 20180362624Abstract: In the field of monoclonal antibodies for therapeutic use, in particular IgG1s for therapeutic use, there is disclosed a method for increasing the binding affinity of an IgG1 vis-à-vis the FcRn receptor, and/or increasing the stability of the complex formed by such IgG1 and FcRn. A related pharmaceutical composition is also disclosed.Type: ApplicationFiled: July 28, 2016Publication date: December 20, 2018Inventors: Valerie GOUILLEUX-GRUART, Herve WATIER
-
Publication number: 20180362625Abstract: The present invention relates to methods of modulating an immune response and/or cytokine production in a subject, the method comprises administering to the subject a compound which modifies C6orf106 protein activity. The present invention also relates to compounds for modifying C6orf106 protein activity in a subject, as well as to screening methods for identifying such compounds.Type: ApplicationFiled: December 2, 2016Publication date: December 20, 2018Inventors: Cameron STEWART, Rebecca AMBROSE, Andrew BEAN
-
Publication number: 20180362626Abstract: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.Type: ApplicationFiled: March 5, 2018Publication date: December 20, 2018Inventors: Robert J. HICKEY, Linda H. MALKAS, Lauren SCHNAPER
-
Publication number: 20180362627Abstract: The present invention is concerned with treatment, prevention, or prevention of progression of myocardial infarction or adverse cardiac remodeling related conditions such as heart failure, aneurysm formation and remote myocardial fibrosis by administering a binding member such as, for example, a neutralizing antibody, binding to fibronectin-EDA, in particular the EDA domain of fibronectin-EDA to a subject in need thereof.Type: ApplicationFiled: June 12, 2018Publication date: December 20, 2018Inventors: Fatih Arslan, Gerard Pasterkamp, Dominicus Paschalis Victor De Kleijn
-
Publication number: 20180362628Abstract: Antibodies that bind to the circumsporozoite protein (CSP) of Plasmodium falciparum. Use of such antibodies as anti-malarial agents, to confer protection against infection by malarial parasites such as P. falciparum by insect vector transmission. Diagnosis of malaria using anti-CSP antibodies. Methods of determining efficacy of candidate vaccine compositions in development and testing of anti-malarial vaccines.Type: ApplicationFiled: May 11, 2018Publication date: December 20, 2018Applicants: KYMAB LIMITED, ATRECA, INC.Inventors: Qi Liang, Sean Matthew Carroll, Daniel Eric Emerling, Allan Bradley, Paul Kellam, Spela Binter, Simon James Watson
-
Publication number: 20180362629Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and caninized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.Type: ApplicationFiled: August 31, 2018Publication date: December 20, 2018Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
-
Publication number: 20180362630Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.Type: ApplicationFiled: September 4, 2018Publication date: December 20, 2018Inventors: Lutz Asmus, Michael Möller, Robert Gurny, P.A. Grimshaw
-
Publication number: 20180362631Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.Type: ApplicationFiled: August 31, 2018Publication date: December 20, 2018Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
-
Publication number: 20180362632Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.Type: ApplicationFiled: August 9, 2018Publication date: December 20, 2018Inventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
-
Publication number: 20180362633Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362634Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362635Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362636Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362637Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362638Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362639Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362640Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362641Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 21, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362642Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: August 30, 2018Publication date: December 20, 2018Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
-
Publication number: 20180362643Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.Type: ApplicationFiled: December 15, 2016Publication date: December 20, 2018Applicant: AMGEN INC.Inventors: Agnes E. HAMBURGER, Cen XU, Hong SUN, Yuan D. SHIH, Dohan WEERARATNE
-
Publication number: 20180362644Abstract: A compound of formula I: wherein Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety.Type: ApplicationFiled: January 10, 2018Publication date: December 20, 2018Inventors: John A. Flygare, Thomas H. Pillow
-
Publication number: 20180362645Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.Type: ApplicationFiled: June 25, 2018Publication date: December 20, 2018Applicant: AMGEN INC.Inventors: Cen XU, Agnes Eva HAMBURGER
-
Publication number: 20180362646Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: ApplicationFiled: May 14, 2018Publication date: December 20, 2018Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Publication number: 20180362647Abstract: The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.Type: ApplicationFiled: December 13, 2016Publication date: December 20, 2018Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: DAVID K. THOMAS, TODD R. GOLUB
-
Publication number: 20180362648Abstract: Antibodies and antigen binding fragments thereof are provided that bind to T-cell receptors (e.g., TCR?), essentially independent of T-cell epitope specificity. Methods for manipulation of T-cells and methods of treatment using such antibodies are likewise provided.Type: ApplicationFiled: September 15, 2016Publication date: December 20, 2018Inventors: Laurence J.N. COOPER, Bipulendu JENA